Clinical trial
Proprotein Convertase Subtilisin Kexin Type 9 Inhibitor in Aortic Stenosis
NCT03051360 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Proprotein Convertase Subtilisin Kexin Type 9 Inhibitor in Aortic Stenosis
- Lead sponsor
- Seoul National University Hospital
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- June 1, 2017
- Completion date
- January 1, 2020
- Enrollment
- 140 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.